Results from existing studies suggest that goji berry polysaccharide is a promising therapeutic agent, particularly in the management of liver disease, hyperlipidemia, and diabetes.
Lycium barbarum polysaccharides (LBPs) have a number of promising therapeutic uses in the liver disease, metabolic disorders, immune dysfunction, aging, neuroprotection, cancer, and ocular surface diseases. These potential applications should be thoroughly assessed through further in vivo studies and ultimately in well-designed randomized controlled clinical trials. One major limitation of current research is a lack of standardization and quality control for the LBP used. The availability of research-grade LBP, of consistent concentration, will help promote further interest and robust research work in this field.
